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Abstract
Background: Although donor dopamine treatment reduces the requirement for post transplantation dialysis in renal
transplant recipients, implementation of dopamine in donor management is hampered by its hemodynamic side-effects.
Therefore novel dopamine derivatives lacking any hemodynamic actions and yet are more efficacious in protecting tissue
from cold preservation injury are warranted. We hypothesized that variation of the molecular structure would yield more
efficacious compounds avoid of any hemodynamic effects.
Methodology/Principal Findings: To this end, we assessed protection against cold preservation injury in HUVEC by the
attenuation of lactate dehydrogenase (LDH) release. Modification of dopamine by an alkanoyl group increased cellular
uptake and significantly improved efficacy of protection. Further variation revealed that only compounds bearing two
hydroxy groups in ortho or para position at the benzene nucleus, i.e. strong reductants, were protective. However, other
reducing agents like N-acetyl cysteine and ascorbate, or NADPH oxidase inhibition did not prevent cellular injury following
cold storage. Unlike dopamine, a prototypic novel compound caused no hemodynamic side-effects.
Conclusions/Significance: In conclusion, we demonstrate that protection against cold preservation injury by
catecholamines is exclusively governed by strong reducing capacity and sufficient lipophilicity. The novel dopamine
derivatives might be of clinical relevance in donor pre-conditioning as they are completely devoid of hemodynamic action,
their increased cellular uptake would reduce time of treatment and therefore also may have a potential use for non-heart
beating donors.
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Introduction
Recently a prospective randomized multicenter trial has
demonstrated a beneficial effect of donor treatment with low-dose
dopamine on immediate kidney graft function [1]. Kidney
transplant recipients who received a graft from a dopamine treated
donor had a significantly decreased need for dialysis after kidney
transplantation compared to the untreated control group. The
salutary effect of dopamine was more pronounced when cold
ischemia time wasprolonged and translatedina bettergraft survival
in this sub-group. In view of the protective effect of dopamine
reported in prospective and retrospective clinical studies [1,2,3,4]
and based on animal studies [5,6] as well as in vitro experiments
[7,8,9], current evidence suggest that dopamine has the propensity
to protect allografts from the deleterious event of cold ischemia
[10,11]. Implementation of low dose dopamine in donor manage-
ment would therefore be genuine rationale for maintaining organ
quality even after prolonged cold storage. The caveat however is
that in brain-dead donors catecholamine clearance is changed and
hence lowdose dopamine treatment might result intachycardia and
hypertension in approximately 15% of the brain-dead donors [12].
In addition, the duration of dopamine treatment is at present not
known. Nonetheless there is a significant relation between the time
of dopamine treatment and efficacy on preventing delayed graft
function [1]. This might be explained by the fact that dopamine is
rapidly degraded in the circulation by monamine oxidase, hence
sufficient tissue dopamine levels can only be obtained by increasing
the treatment dose or time of dopamine treatment. The former
cannot be used in brain dead donors as this would increase the
incidence of tachycardia and hypertension.
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9713The use of non heart beating donors is world-wide increasing.
Yet, the incidence of delayed graft function is significantly
increased when renal allografts from such donors are used
[13,14,15]. Since dopamine treatment in these donors can only
be initiated after cardiac arrest, and the time required for
obtaining sufficient tissue dopamine levels might take several
hours, dopamine treatment of non heart beating donors is not an
option to reduce the incidence of delayed graft function.
Given these limitations of dopamine, there is an unmet need
for compounds that lack hemodynamic action and yet are more
efficacious than dopamine. To meet this objective, we delineated
the structural entities within catecholamine mimetic compounds
that convey protection against hypothermic injury by systematic
variation of their molecular structure. We aimed to synthesize
compounds devoid of any hemodynamic side effects that protect
endothelial cells against cold preservation injury more
potently.
Results
Protection against hypothermic injury depends on
lipophilicity and redox activity
New compounds were synthesized as described in the method
section and tested for their protective effects against hypothermic
injury. To this end HUVEC were pre-incubated for 2 hrs and
EC50 values were calculated for each substance based on the
LDH release after 24 hrs cold storage at 4uC( Table 1).
Modification of dopamine by an alkanoyl group (Figure 1,
compounds 5–8) increased logP values and was associated with
increased efficacy as indicated by a 40-fold decrease in EC50
values compared to dopamine. Among the protective compounds,
the EC50 values correlated with their calculated logP values
(figure 2). These results suggest that the more lipophilic a
compound is the more potently it protects against hypothermic
injury up to a logP value of 2.5.
In addition to its increased lipophilicity, dobutamine (com-
pound 4), which is characterized by an EC50 value of 5 mM,
contains a second aromatic residue. Therefore, we next addressed
the question whether 2 aromatic residues would further increase
the protective capacities of these compounds. Compounds 9 and
10 showed decreased EC50 values compared to dopamine
(compound 1) but were less effective than the chemically related
dobutamine (compound 4) despite having comparable logP values.
These data demonstrate that the protective effect of compounds
with 2 aromatic residues is not superior to those with 1 aromatic
residue only.
Removal of the 3-OH group from the highly protective
compound 5 yielding compound 11 further increased lipophilicity
(logP 3.526 vs. 2.929) but abolished the protective effect (EC50
.100 mM vs. 2.1 mM60.2). This could indicate that either a
strongly reducing catechol function is required for maximal
protection, or suggest a receptor mediated phenomenon that
recognizes the intact dopamine fragment only. To test the
hypothesis that the protective effect of catechol compounds
depends on its reducing capacity and is independent of the
dopamine structure, we synthesized the octylamide derivates
(compounds 18–23) of all possible dihydroxy benzoic acids
(compounds 12–17), including 3 reducing (compounds 12–14
and 18–20) and 3 non (or weakly) reducing (compounds 15–17
and 21–23) structures. While the free acids (compounds 12–17)
were all ineffective (EC50 .100 mM), the reducing octylamides
(compounds 18–20) revealed EC50 values between 1.2 and 6 mM.
In addition, all non-reducing octylamides (compounds 21–23)
were ineffective despite comparable logP values.
Taken together, all compounds identified as protective cover
diverse structures at the benzene nucleus and share only one
common property, i.e. their reducing capacity. Therefore, it is
unlikely that a specific receptor-mediated process underlies the
protective properties of catecholamines and related substances.
Subsequently, to investigate whether the protective properties of
these compounds reflect a general anti-oxidative effect, we also
employed additional reducing compounds and specific inhibitors
of oxidative pathways. Both ascorbate and N-acetyl cysteine were
not protective against hypothermic injury when used up to
300 mM (data not shown). Similarly, increasing doses up to 3 mM
of apocynin, an inhibitor of the NAPDH oxidase or up to 300 mM
of tempol (2,2,6,6-tetramethylpiperidin-n-oxyl), a scavenger of
reactive oxygen species, did not confer cellular protection (data not
shown).
N-acylation of dopamine abolishes the hemodynamic
effects in vivo
We next sought to test potential hemodynamic side effects of the
highly protective compound 5 in vivo. To this end, male Fisher rats
received 3 consecutive intravenous injections of N-octanoyl-
dopamine (0.05 mmoles/kg body weight) and systemic blood
pressure was continuously monitored by an arterial catheter. As
Table 1. Chemical characteristics of compounds used in this
study.
Compound
# Fig
EC50
[mM]
strong
reducing agent?
logP
(calc.)
11 A ,75 + 0.169*
21 A .100 + 20.989*
31 A .100 + 20.685*
41 A 5+ 2.433*
5 1B 2.160.2 + 2.929
6 1B 0.960.2 + 3.987
7 1B 1.260.2 + 5.045
8 1B 1.360.2 + 6.103
91 B 1 2 61 + 2.253
10 1B 961 + 1.852
11 1B .100 2 3.526
12 2 .100 + 1.622
13 2 .100 + 1.062
14 2 .100 + 1.622
15 2 .100 2 1.622
16 2 .100 2 0.992
17 2 .100 2 2.252
18 2 1.260.1 + 4.621
19 2 2.460.2 + 3.741
20 2 661 + 4.6
21 2 .100 2 4.621
22 2 .100 2 3.671
23 2 ,90 2 3.741
The protective effect of various compounds against cold-induced endothelial
cell injury expressed as the concentration required to inhibit 50% LDH release
and lipophilicity expressed as logarithm of the partition coefficient (logP,
*denotes experimental values taken from public sources). Depicted are mean
values 6 SD (n=3).
doi:10.1371/journal.pone.0009713.t001
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PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9713Figure 1. Molecular structures of compounds used in this study. (A) Catecholamines previously reported to exert a protective effect on
endothelial cells against cold damage. (B) Structurally related derivatives of dopamine synthesized and used in this work. (C) Chemically possible
isomers of the dihydroxybenzoyl fragment used as free acids (R = OH) or as much more lipophilic n-octyl amides (R =NH-C8H17). The compounds
with hydroxy groups in ortho or para position (2,3; 3,4 or 2,5) present with strong reducing capacities, while the other isomers are much weaker
Cell Protection by Catechols
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9713expected the loss of charge at nitrogen in N-octanoyl dopamine
(compound 5) abolished any effect on mean arterial blood pressure
(figure 3). To exclude any potential competitive inhibition of
dopaminergic receptors by compound 5, a single dose of
dopamine (0.05 mmoles/kg body weight) was administered 100
minutes after the initial N-octanoyl dopamine injection. Animals
responded with a significant increase in mean arterial blood
pressure within 20 minutes (83 mmHg 6 4 vs. 162 mmHg 6 6).
Thus, N-acylation of dopamine impairs receptor binding and does
not yield dopamine antagonistic products.
Increased lipophilicity enhances cellular uptake
Hypothermia leads to a redox imbalance with a relative
increase in ROS. Mitochondrial function and the generation of
ATP necessary for the generation of redox equivalents are
greatly impaired. Recently, we have shown that dopamine
preserves mitochondrial function during cold storage in HU-
VEC [7,8]. Therefore, we tested the hypothesis that N-acylation
of dopamine would increase cellular and mitochondrial uptake
which would contribute to the increased protective effects of
these compounds. To this end we synthesized [
3H] labelled
compound 5 from 7,8-[
3H] dopamine and studied its subcellular
distribution after 2 hrs incubation at 37uC. Based on radioac-
tivity, total uptake of compound 5 was approximately 4-fold
greater compared to dopamine when employed at the same
concentration (figure 4A). Increased cellular uptake was also
accompanied by increased relative uptake in the mitochondria
and a decrease in the cytosolic compartment while the
membrane fraction showed comparable levels of [
3H]
(figure 4B). In mitochondria, the relative concentration of
compound 5 was increased about 2-fold, corresponding to
approximately 8 times (in absolute values) more radioactivity in
the mitochondria compared to dopamine.
Discussion
Novel, experimental strategies to further reduce pre-transplan-
tation injury include treatment of brain-dead heart-beating donors
prior to organ explantation. Pre-treatment with catecholamines is
positively associated with improved organ function following
transplantation [1,2,3,4]. The aim of this study was to elucidate
the structural entities of catecholamines and related substances
that confer protection against hypothermic injury.
The first major finding of this study was that the single common
feature of all protective compounds tested was the presence of 2
hydroxy groups at the benzene nucleus, located either in ortho or
in para position. Additional substituents were of minor impor-
tance. Ortho and para isomers are known to be strong reducing
agents due to the ease of quinone formation, which cannot occur
in meta isomers. The reducing characteristics are in line with
previous findings where the loss of its reducing capacity by
oxidation abolished the protective effect of dopamine [9].
In addition, sufficient lipophilicity was required for catechol-
amines to protect against hypothermic injury. As expected, N-
acylated dopamine derivatives entered the cells more easily than
unmodified dopamine and accumulated to a greater proportion in
the mitochondrial compartment. Although the calculated logP
values may differ from experimentally determined values, the
presented numbers show significant agreement with previously
published data which are available for some compounds. As logP
refers to uncharged compounds, additional effects cannot be
excluded. In addition, dihydroxybenzoic acids are present in their
ionized forms at physiological pH, which may influence their
cellular uptake and thus protective potency. Within the series of
uncharged amide compounds, the assumed correlation of logP
with their respective protective effects appears to be valid. The aryl
derivates (compound 9+10) exhibit a slightly lower efficacy as
expected from their logP value. However, in contrast to catechol
derivates with comparable logP values they lack an extended alkyl
chain that would enable them to insert into lipid membranes more
easily.
reducing agents. (D) Structure of the chemically unrelated substances apocynin, a NAPDH oxidase inhibitor, and tempol (2,2,6,6-
tetramethylpiperidine-1-oxyl), a stable radical often employed as a low molecular weight superoxide dismutase mimetic.
doi:10.1371/journal.pone.0009713.g001
Figure 2. EC50 and logP values follow a sigmoid Boltzmann
distribution. EC50 values expressed as mean (n=3) are plotted
against calculated logP values for the reducing compounds (1–10 and
18–20) listed in table 1. A sigmoid (Boltzmann) line was found to fit the
data set with A1=1.22, A2=1000, x0=20.67, dx=20.58.
doi:10.1371/journal.pone.0009713.g002
Figure 3. Hemodynamic activity of N-octanoyl-dopamine
(compound 5). Mean arterial blood pressure was measured online
in anaesthetized rats while infusing equimolar concentrations of
compound 5 (18 mg/kg/min) or dopamine (10 mg/kg/min). Depicted
are mean values 6 SD (n=3).
doi:10.1371/journal.pone.0009713.g003
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catecholamines [7,8]. Several lines of evidence support this
hypothesis. First, hypothermia reduces respiratory chain activity
resulting in depletion of ATP and reduction equivalents, leading to
a redox imbalance with a relative increase in ROS [8].
Catecholamines present with strong reducing characteristics and
could prevent, at least in parts, mitochondrial injury caused by
increased ROS. Second, increased ATP consumption causes a
breakdown in mitochondrial membrane potential leading to
calcium accumulation [16], which further aggravates mitochon-
drial dysfunction. Dopamine has been shown to delay these effects
in HUVEC during cold storage [7,8].
A third major finding was that the protective effects of
catecholamines are independent of any receptor-mediated process.
Highly specific structural entities are required for a ligand to
interact with its specific receptor, which can be expected to
respond much more selectively to significant molecular modifica-
tions. Therefore, the variety of dihydroxyphenyl structures that
present with protective characteristics strongly disfavours any
involvement of a specific receptor mediated process. We also
tested and excluded that N-octanoyl-dopamine (compound 5)
exhibits any hemodynamic effects in vivo and does not function as a
competitive receptor inhibitor either. These results extend
previous reports where we demonstrated that the protective effect
of dopamine is independent of de novo protein synthesis.
Interestingly, a relative short incubation time up to 30 minutes is
sufficient to achieve maximal protection (data not shown). Taken
together, these results prove that the protective effect of
catecholamines lies within their molecular moieties.
Based on their chemical structure catechols are also able to form
complexes with free iron ions. Several studies reported an increase
in the chelatable iron pool during hypothermic preservation which
further contributes to cellular injury [17,18,19]. On the basis of
our findings, we can exclude a significant contribution of
catecholamines and their capacity to complex iron in relation to
their protective effect for the following reason. In most studies on
mixed ligand complexes of iron, catechol yields the most stable
complexes. While hydroxy groups at the benzene nucleus in meta
and para position, i.e. resorcinol and hydroquinone (or their
functional derivatives) usually result in equally stable iron
complexes, they yield much less stable iron complexes than
catechol (ortho) compounds. In our study, compounds with para-
or ortho-dihydroxy groups were equally protective against cold
preservation injury, while the meta derivatives were not protective.
Thus, there was no correlation between the capacity of catechols
to protect against hypothermic injury and their expected ability to
form iron complexes.
Based on the structural requirements we hypothesize that
insertion of the compounds into lipid compartments might prevent
oxidative damage at or near hydrophobic compartments.
Regardless of the mechanism, an efficient protective substance
requires an ortho or para dihydroxybenzene partial structure, is
preferably uncharged with an alkyl chain and exhibits an overall
lipophilicity exceeding a logP value of 2.5.
In conclusion, we have demonstrated that a strong reducing
capacity by suitable substituents at the benzene nucleus as well as
sufficient lipophilicity mediate the protective effect of catechol-
amines against hypothermic injury. Dihydroxy phenolic substanc-
es that lack any hemodynamic effects can also fulfil these structural
requirements. Hence, these novel compounds might be considered
for donor pre-conditioning to protect allografts against cold
preservation injury without influencing blood pressure in the
donor. As cellular uptake is significantly increased, the use of these
novel compounds would decrease the time required for treatment
and, therefore, offer a mean to reduce the incidence of delayed
graft function when renal allograft of non heart beating donors are
used.
Methods
Cell isolation and culture
Human umbilical vein endothelial cells (HUVEC) were isolated
as described previously and cultured in endothelial cell growth
medium (Promocell Heidelberg, Germany) in T25 flasks (Greiner,
Frickenhausen, Germany) coated with 1% gelatine (Fluka, Neu-
Ulm, Germany).
Hypothermic preservation injury
Hypothermic preservation injury of HUVEC was assessed by
lactate dehydrogenase (LDH) release. LDH assays were performed
using a commercial system as recommended by the manufacturer
(Roche Diagnostics, Mannheim, Germany). Briefly, HUVEC were
seeded in 24-well plates (Greiner), grown until confluence and
Figure 4. Subcellular distribution of radioactivity from N-
Octanoyl dopamine or dopamine. HUVEC were incubated for 2 hrs
with equal amounts of [
3H]-octanoyl-dopamine (compound 5) or 7,8-
[
3H]-dopamine. Results are expressed as mean 6 SD (n=3) incorpora-
tion relative to the amount of radioactivity applied. (A) Total cellular
uptake of [
3H]-octanoyl-dopamine (compound 5) or 7,8-[
3H]-dopamine
relative to total amount applied. (B) Subcellular distribution of
radioactivity from [
3H]-octanoyl-dopamine (compound 5, hatched bars)
or 7,8-[
3H]-dopamine (grey bars), relative to total radioactivity uptake.
doi:10.1371/journal.pone.0009713.g004
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washed three times with 1 ml of PBS and stored for 24 hrs at 4uC
in phenol red free medium (PAA, Pasching, Austria). 100 ml
aliquots of supernatants were used to determine LDH release with
phenol red free medium as blank control. Experiments were
performed in triplicate (n=3) and results are expressed as OD at
490 nm corrected for the blank.
Synthesis of compounds
Test compounds were synthesized from commercially available
precursors (all from Fluka unless stated otherwise) and were
purified by recrystallization to homogeneity as demonstrated by
thin layer chromatography (TLC). Samples investigated by NMR
(Bruker AC250) yielded spectra in accordance with the expected
structures. LogP values were calculated using the engine at www.
daylight.com/daycgi/clogp or at www.molinspirations.com. All
compounds synthesized in this study are shown in Table 1.
General procedure for acylated dopamine derivates
Carboxylic acids were converted to their mixed anhydride
derivatives by reaction with ethyl chloroformate and the mixed
anhydride incubated with dopamine dissolved in dimethyl
formamide (DMF) at 50 mg/ml, in the presence of N-ethyl
diisopropylamine. Ethyl acetate was added to the mixture, and
after washing with sodium hydrogen carbonate and diluted
sulphuric acid, evaporation of the solvent yielded the acylated
product.
General procedure for dihydroxybenzoyl amides
Stoichiometric amounts of dihydroxybenzoic acid, amine and
dicyclohexyl carbodiimide were dissolved in THF and kept
overnight at room temperature. After filtration, the solution was
evaporated, re-dissolved in ethyl acetate and washed sequentially
with diluted acid, brine, and sodium bicarbonate. After drying, the
solvent was evaporated.
[
3H]-N-octanoyl dopamine (compound 5)
[
3H]-N-Octanoyl dopamine was synthesized from 1.85 MBq
7,8-[
3H]-dopamine (Amersham, Freiburg, Germany). About 65%
of radioactivity was recovered. TLC, spraying with En
3hance
(Perkin Elmer, Waltham, MA) and 7d exposure on X-ray film at
280uC revealed .90% purity as determined by comigration of
nonradioactive N-octanoyl-dopamine.
Tracer studies and subcellular fractionation
HUVEC cultured to confluence in T175 flasks (Greiner) were
incubated with 925 kBq (25 mCi) of [
3H]-octanoyl-dopamine or
[
3H]-dopamine for 2 hrs. Hereafter the cells were washed and a
subcellular fractionation was performed as recommended by the
manufacturer (Geno Technology, St. Louis, MO). Briefly, cell
lysates were prepared by homogenization were centrifuged; the
supernatants were further centrifuged for 2 min at 4,000 x g.
Cytosolic proteins and cellular organelles were present in the
supernatant (S1). The pellet (P1) contained cell membranes and
the nuclear fraction. S1 was further centrifuged (20 min, 10,000 x
g) to separate cellular organelles (pellet P2) from cytosolic proteins
(supernatant S2). P2 was subjected to hypotonic shock followed by
centrifugation (20 min 10,000 x g) to separate mitochondria (pellet
P3) from lysosomes (supernatant S3). Supernatant S2 was further
centrifuged for 1 h at 100,000 x g. Purity of the subcellular
fractions was tested by Western blotting. Radioactivity was
measured in aliquots collected directly after douncing and in
aliquots of P1, P3 and S2. Samples were mixed with 3 ml
scintillation cocktail and counted in a Beckman LS6000.
Measurements of hemodynamic parameters
Male Fisher rats (250 g) were anaesthetised with ketamine and
xylazine. Dopamine or N-octanoyl-dopamine (0.05 mmoles/kg
body weight) was infused into the femoral vein. Systemic blood
pressure (mean arterial pressure, mmHg) was continuously
measured by a femoral arterial catheter (SIMS Portex, UK). All
procedures were performed according to the guidelines of the
American Physiological Society and were approved by the local
authorities (Regierungspraesidium Karlsruhe AZ 35-9185.81/G-
61/05).
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